June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Evaluation of the anti-inflammatory efficacy of high oral bioavailability Curcumin as add-on treatment in non-infectious uveitic cystoid macular edema by SD-OCT and OCT-Angiography: preliminary results
Author Affiliations & Notes
  • Pia Allegri
    Ocular Inflammatory Diseases, Rapallo (Genova) Hospital, Chiavari, Genova, Italy
  • Roberta Rissotto
    Ophthalmology, Catholic University of the Sacred Heart, Rome, Rome, Italy
  • Federico Rissotto
    Ophthalmology, University of Genova, Genova, Genova, Italy
  • Alessandro Masala
    Ocular Inflammatory Diseases, Rapallo (Genova) Hospital, Chiavari, Genova, Italy
  • Maria Grazia Crivelli
    Hospital Pharmacy, ASL 4 Health Regional System, Sestri Levante, Genova, Italy
  • Anna Rita Blanco
    Medical Research, Alfa Intes, Casoria, Napoli, Italy
  • Ugo Murialdo
    Ocular Inflammatory Diseases, Rapallo (Genova) Hospital, Chiavari, Genova, Italy
  • Footnotes
    Commercial Relationships   Pia Allegri, None; Roberta Rissotto, None; Federico Rissotto, None; Alessandro Masala, None; Maria Grazia Crivelli, None; Anna Rita Blanco, None; Ugo Murialdo, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 5356. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Pia Allegri, Roberta Rissotto, Federico Rissotto, Alessandro Masala, Maria Grazia Crivelli, Anna Rita Blanco, Ugo Murialdo; Evaluation of the anti-inflammatory efficacy of high oral bioavailability Curcumin as add-on treatment in non-infectious uveitic cystoid macular edema by SD-OCT and OCT-Angiography: preliminary results. Invest. Ophthalmol. Vis. Sci. 2020;61(7):5356.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the efficacy and safety of a curcumin formulation with hydrophilic carrier (CHC; Diabec® - AlfaIntes, Italy) as an adjuvant treatment in adults suffering from recent onset of non-infectious inflammatory cystoid macular edema (CME).

Methods : A monocentric parallel group clinical study was carried out from March to November 2019, including a control group (standard therapy) and a curcumin add-on treatment group (standard therapy + Diabec®). According to the protocol, one capsule twice a day of Diabec® was administered for six months in association with standard systemic therapy (oral prednisone 15 mg/day and/or methotrexate 15 mg/week) in the curcumin-treatment study group. Reduction in central foveal thickness (CFT) assessed by Heidelberg Spectralis OCT and best-corrected visual acuity (BCVA - ETDRS charts) were the main analysed outcomes. Secondary end-point was the evaluation of the Foveal Avascular Zone (FAZ) variations with Optovue AngioVue angiography, before and after 6 months.

Results : Forty-eight eyes of 26 patients (17 females and 9 males, mean age 53.4 years +1.3 months) were included into the study, with an average follow-up (f/u) of 6 months ±1 week. Eighteen patients were affected by posterior uveitis, 3 by pan-uveitis and 5 by intermediate uveitis, evenly distributed between the two groups. In the curcumin-treated group (25 eyes) CFT gap from T0 to T6 was significant (p < 0.05) and CFT decreased from 320 μm (± 96.7) to 283 μm (± 46.3). Control group (23 eyes) showed no variations in CFT (T0=299±71 μm and T6=282 ± 51). Mean visual acuity improvement at T6 was 5.8 ETDRS letters in the experimental treatment group (p<0.01). No significant difference in 6 months was registered in the control group. No adverse events were recorded.

Conclusions : An oral formulation of curcumin in hydrophilic carrier (CHC; Diabec®) as adjuvant treatment resulted statistically effective and safe at 6 months in eyes affected by recent onset non-infectious inflammatory CME. These patients showed an anatomical and functional improvement compared to the standard therapy control group. These preliminary results will be assessed at 12 months.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×